Celularity is a biotechnology company that harnesses the power of placenta-derived cells and tissue to create regenerative health solutions. These therapies have the potential to rid the body of life threatening disease and ultimately extend the human lifespan. Celularity's intellectual property and research portfolio consists of 800 patents as well as pre-clinical and clinical assets, including CAR constructs for allogeneic CAR-T/NK products, licenses to 100+ immunotherapy assets, and commercial stage biosourcing and functional regeneration businesses.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/16/18 | $250,000,000 |
Celgene Corporation Dreyfus Family Office Genting Group Heritage Group Human Longevity Section 32 Sorrento Therapeutics United Therapeutics | undisclosed |
